TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00166049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Partnership Intervention (FPI)
Description: HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient and Family Education
Description: HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient and Family Education
Description: HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
Study: NCT04741737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reSLNB arm
Description: Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.
Study: NCT01020214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benicar HCT® Tablets 40 mg/25 mg
Study: NCT00166049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care with educational material
Description: Usual care with provision of printed educational material, provided once at baseline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care with educational material
Description: Usual care with provision of printed educational material, provided once at baseline

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care with educational material
Description: Usual care with provision of printed educational material, provided once at baseline
Study: NCT02932813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK Program
Description: Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
Study: NCT02599922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-PR1.7-hCNGB3
Description: rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Study: NCT02804399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: 100 mg oral dose on day 1 in period 1 and on day 8 in period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600 mg QD from day 1 to day 12 in period 2.
Study: NCT03159351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS treatment
Description: active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
Study: NCT03636373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Study: NCT01010087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: standard (75 mg bid) or high-dose (225 mg bid) oseltamivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
Study: NCT01280604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 54mg
Description: Subjects will receive fenofibrate 54mg daily.
Study: NCT02119338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ala
Description: dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
Study: NCT04429802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered
Study: NCT04213677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
Study: NCT00085397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-tumor fusion vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given IV
Study: NCT01472614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
Study: NCT03387813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS™ HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS™ HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS™ HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
Study: NCT00459797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (reusable) Glidescope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use Glidescope videolaryngoscope
Study: NCT03625453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: 8 weeks with daily administration
Study: NCT04160806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Study: NCT00358644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
Study: NCT04276298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole cream
Description: 10% metronidazole applied rectally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole and Diltiazem cream
Description: Combination Metronidazole and Diltiazem applied rectally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole and Lidocaine cream
Description: Combination metronidazole and lignocaine applied rectally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole, Diltiazem and Lidocaine cream
Description: Combination of all active agents tested applied rectally
Study: NCT02628483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 1000mg fish oil per capsule (325mg EPA + 225mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: 1000mg fish oil per capsule (300mg EPA + 200mg DHA)
Study: NCT04380883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnoSEAL+TRB
Description: InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRB alone
Description: TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
Study: NCT03289702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORETOX®
Description: Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
Study: NCT01405677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epaxal 0.25 mL
Description: 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epaxal 0.5 mL
Description: 24 IU hepatitis A antigen coupled to IRIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Junior 0.5 mL
Description: 720 EU hepatitis A antigen absorbed onto aluminum hydroxide
Study: NCT03989921

Intervention type: OTHER
Intervention: no intervention. observational study
Description: no intervention. observational study

Intervention type: OTHER
Intervention: no intervention. observational study
Description: no intervention. observational study
Study: NCT00535093

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: rapid streptococcal testing
Description: Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
Study: NCT03310398

Intervention type: BEHAVIORAL
Intervention: NeuroImaging
Description: standard anatomical and functional imaging

Intervention type: BEHAVIORAL
Intervention: NeuroImaging
Description: standard anatomical and functional imaging

Intervention type: BEHAVIORAL
Intervention: Psychophysiological
Description: Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram

Intervention type: BEHAVIORAL
Intervention: Psychophysiological
Description: Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
Study: NCT00746356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing of the autocapture features of the device
Description: Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing of the autocapture features of the device
Description: Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
Study: NCT04115267

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Combined modality
Study: NCT04833244

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triangular Forearm Support
Description: The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be asked to raise arms overhead for 45 seconds.
Study: NCT05111743

Intervention type: DRUG
Intervention: Brolucizumab
Description: Participants received brolucizumab injection during the index period
Study: NCT03096756

Intervention type: DRUG
Group type: OTHER
Intervention: GC4702 dry powder
Description: 5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg

Intervention type: DRUG
Group type: OTHER
Intervention: GC4702 lipid suspension
Description: 112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg

Intervention type: OTHER
Group type: OTHER
Intervention: GC4419 IV
Description: infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Dry Powder
Description: Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo lipid suspension
Description: Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Condition
Description: For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4702 lipid suspension - Part 2
Description: Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
Study: NCT02240797

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging
Study: NCT00827736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISDN ointment
Description: application of ISDN 1% ointment 6 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)
Study: NCT04344665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Care and Remote Automated Monitoring
Description: Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.